Researches and develops drugs, diagnostics and other therapeutic products

Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs.

BioRestorative Therapies is a development stage company, develops medical procedures using cell and tissue protocols, primarily involving adult stem cells, designed for patients to undergo minimally invasive cellular-based treatments. The company focuses on the development of the ThermoStem Program that engages in the use of brown fat in connection with the cell-based treatment of Type 2 diabetes, obesity, hypertension, other metabolic disorders, and cardiac deficiencies, as well as is involved in the study of stem cells, several genes, proteins, and/or mechanisms, which are related to these diseases and disorders. It also focuses on the development of brtxDISC (Disc Implanted Stem Cells) Program for the adult stem cell treatment of disc and spine conditions, including bulging and herniated discs.

Cellectis AB, a subsidiary of Takara Holdings, Inc., is a Swedish company located in Gothenburg. The firm manufactures and distributes stem cell-related products. On September 04, 2014 Takara Bio, Inc. acquired Cellectis AB from Cellectis SA.

International Stem Cell Corp. operates as a clinical stage biotechnology company. The firm engages in the development of therapeutic and biomedical products. It operates through the following segments: Cosmetic Market, Biomedical Market and Therapeutic Market. The Cosmetic Market segment develops, manufactures and markets cosmetic skin care products based on the company's proprietary parthenogenetic stem cell technology and targeted small molecule technology. The Biomedical Market segment is involved in the development, manufacture and commercialization of primary human cell research products. The Therapeutic Market segment focuses on the research and development of human parthenogenetic stem cells for the treatment of diseases of the central nervous system, liver diseases and is currently conducting clinical trials for the treatment of Parkinson's disease. The company was founded by William B. Adams, Kenneth C. Aldrich and Gregory S. Keller in June 2005 and is headquartered in San Diego, CA.

Vivalis SA manufactures human and animal vaccines. The firm specializes in the research and development of vaccines and antiviral molecules, as well as in recombinant therapeutic protein and monoclonal antibody expression systems development. The firm's embryonic stem cells are used for practical applications in human and animal health. It also helps its clients in a case by case basis for the development of processes in the frame of service agreement. The company was founded in April 1999 and is headquartered in France.

The Research Authority serves as the administrative and financial framework for research activities, scientific experiments and technical analyses carried out by Technion faculty, and TRDF staff. The missions of the Research & Development Division are: - Location, collection, processing and distribution of information concerning local and international research funding - Assistance in locating appropriate funding sources for Technion researchers - R&D information management services and in-campus marketing - Guidance and administrative services for Technion researchers in submitting research proposals to granting agencies and business entities - Management of contractual engagements with granting agencies and business entities - Contractual and budgetary administration of research grants and other accounts

Stem Cells Spin is engaged in the development, production, marketing, and sale of natural regenerative products for the dermo-cosmetic and veterinary care markets. It provides Revitacell biodermocosmetcs skincare products, including face therapy, hair therapy, eyelashes therapy, regenerating cream-serum day, regenerating and nourishing cream-serum night, eye zone regenerating concentrate, regenerating face balm for men, bust set, hand set, and face set products, as well as regenerating and anti-aging MIC-1 mesotherapy; and veterinary care products consisting of regenerating care balms, antibacterial regenerating ointments, and regenerating and warming rub ointments under the Velvetyna brand name.

Repairon GmbH engages in the development, manufacture, and commercialization of induced pluripotent stem cell based tissues for organ repair. It offers therapeutic products such as tissue patches and pouches for the treatment of patients with heart failure caused by ischemic and dilatative cardiomyopathies. The company was founded by Wolfram Zimmermann in 2004 and is headquartered in Goettingen, Germany.

Shiok Meats is cellular aquaculture and cell-based meat company. With a mission to bring clean and healthy meats and seafood by harvesting from cells instead of animals. Shiok Meats brings cell-based crustacean meats that are animal-, health- and environment-friendly. Shiok Meats was founded in 2018 and is headquartered in Central Region, Singapore.

ES Cell International Pte Ltd. develops human embroyonic stem cell technologies for research and commercial applications. It develops an array of intellectual property in the fields of drug discovery, diagnostics, and therapeutics based on stem cell technology. The company was founded by Ariff Bongso, Robert Klupacs, Martin F. Pera, Reubinoff Benjamin and Alan Osborne Trounson in 2000 and is headquartered in Singapore.

Provides research on animal and plant healthcare, material sciences and biotechnology

Reliance Life Sciences is a diverse and integrated biotechnology initiative of the Reliance Group of companies. The Reliance Group is India’s largest private sector enterprise, with annual revenues of US$ 66.8 billion. The Group’s activities span oil and gas exploration and production, petroleum refining, petrochemicals, polyester, plastics, organized retailing and telecom. The Group’s flagship company Reliance Industries Limited is the largest private sector company and a Fortune Global 500 company. Reliance Life Sciences is part of the Promoter Group of Reliance Industries Limited. RLS was established to develop business opportunities in medical biotechnology with key initiatives in biopharmaceuticals, pharmaceuticals, regenerative medicine, clinical research and molecular diagnostics.

SL BIGEN is a research and development business that aims to save patients' lives through bio-genetic engineering. SL BIGEN is working on two projects: I a first-in-class mesenchymal stem cell line engineered to express disease-specific therapeutic genes, and (ii) a multi-engineered natural killer cell line expressing fourth generation chimeric antigen receptors. Cancer and neurological illnesses are among the therapeutic areas covered by the company.

Engages in research and development of biological products

The Board of Trustees of the University of Illinois, part of University of Illinois, is a company headquartered in Urbana, IL, that trusts Except Educational Religious.

The Rural Development Administration (Korean: 농촌진흥청; Hanja: 農村振興廳, RDA) is one of an agriculture organizations in South Korea and is run under the Ministry of Agriculture, Food and Rural Affairs. The headquarters are in Wansan-gu, Jeonju.

The Buck Institute is the nation’s first independent research facility focused solely on understanding the connection between aging and chronic disease. Their mission is to increase the healthy years of life. At the Buck Institute, world-class scientists work in a uniquely collaborative environment to understand how normal aging contributes to the development of conditions specifically associated with getting older such as Alzheimer’s and Parkinson’s diseases, cancer, stroke, osteoporosis, heart disease, diabetes, macular degeneration and glaucoma. Their interdisciplinary approach brings scientists from disparate fields together to develop diagnostic tests and treatments to prevent or delay these maladies. The stakes have never been higher. While it’s true that people are living longer, those “extra” years are often marked by disability and pain. In addition to personal hardship, there is also a cost to society. The financial burden of treating the chronic diseases of aging is expected to rise steadily as Baby Boomers get older. There is an urgency to Their mission.